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Objectives: The degree of lymphoceles prevention was assessed using collagen patches 
coated with human coagulation factors (TachoSil, Nycomed International Management 
GmbH, Zurich, Switzerland). The study enrolled 50 consecutive patients with endometrial 
and cervical cancer stages IB to II who had undergone open hysterectomy and pelvic 
lymphadenectomy (PL). In addition, the drainage volumes of 22 patients with hypertension 
were compared to that of the rest of the study population. Furthermore, occurrence of 
lymphocele in patients with endometrial and cervical cancer were compared after completion 




Material and methods: Patients were simultaneously randomized in two groups: as a control 
(side without TachoSil applied) and study group (side with TachoSil applied). All surgical 
parameters were collected, and patients underwent ultrasound examination on postoperative 
days 1, 6, and 30, and at the end of treatment.  
Results: The TachoSil Group showed a lower drainage volume, 30 days after surgery, while 
outflow of fluid occurred in 11 (22%) of all TachoSil Group cases and 22 (44%) of all control 
group cases. Furthermore, two patients in the control group had symptomatic lymphocele, 
while the same number of cases was observed in the TachoSil Group. However, the TachoSil 
Group demonstrated a decreased tendency to lymphocele occurrence after the end of adjuvant 
therapy. Here, patients with the collagen patch developed lymphocele in 12% of all cases, as 
opposed to 18% without TachoSil. 
Conclusions: TachoSil is a useful support treatment option for reducing drainage volume and 
preventing lymphocele development after lymphadenectomy. 
 





Lymphoceles are the most common postoperative complications of pelvic 
lymphadenectomy among patients with endometrial and cervical cancer [1]. Incidences of 
lymphocele occur in 1% to 50% of all cases and depend on the surgical technique used and 
the extent of lymphadenectomy [2]. Symptoms are pelvic pain, leg edema, gastrointestinal 
obstruction, obstructive uropathy, and deep vein thrombosis, sepsis and lymphatic fistula 
formation. Easy migration of lymph from lymphatic vessels into tissues results from low 
concentration of coagulation factors, absence of thrombocytes and lack of smooth muscle in 
the lymph vessel walls. All these factors prevent lymph vessel walls from shrinking. There is 
also an accumulation of high-protein interstitial fluid with a low oxygen content and 
proteolytic activity that results in a chronic inflammation. Lymphoceles are clinically 
significant as they increase the cost of treatment and they prolong hospitalization, reduce the 
quality of patients’ life, increase morbidity and, what is very important, delay the onset of 
adjuvant oncological treatment. Due to the lack of methods of intraoperative diagnosis of 




closure of lymphatic vessels, there is a great need to develop methods for effective 
lymphocele prophylaxis. 
Several techniques have been described to decrease the incidence of lymphocele. 
Some authors suggest that the peritoneum should be left open over the lymphadenectomy sites 
at the end of the procedure and drains should not be placed. Moreover, omentoplasty should 
be encouraged. Others suggest that postoperative octreotide therapy seems beneficial, but the 
role of this drug in pelvic oncological surgery remains to be determined [3]. Hence, further 
studies are needed to assess the potential benefits of new practices. 
TachoSil® is a fibrin-collagen patch coated with human coagulation factors and is 
intended to support surgical hemostatic interventions. The specific, hexagonal, multimodal 
structure of the collagen sponge covered with a coating of human fibrinogen and thrombin 
provides more than double the adhesion strength in comparison to standard tissue adhesion 
[7]. TachoSil contains human fibrinogen and thrombin in the form of a dry coating located on 
the surface of the collagen sponge. On contact with a wound, the fibrinogen is transformed 
into fibrin monomers that spontaneously polymerize to the fibrin clot. This effect is 
responsible for the adhesion of the collagen sponge to the wound surface and the sealing of 
the lymphatic vessels. The use of TachoSil in the prevention of lymphocele can thus be 
justified via its unique adhesive properties. The efficacy and safety of TachoSil® has been 




The aim of the study was to evaluate the effectiveness of TachoSil in the prevention of 
lymphocele after the performance of lymphadenectomy in patients diagnosed with 
endometrial and cervical cancer. The primary endpoints were the incidence and volume of 
lymphocele. The period of hospitalization, duration of lymphatic drainage and the period of 
implementation of adjuvant treatment were secondary endpoints.  
 
 MATERIAL AND METHODS 
The study was approved by the Bioethics Committee of the Medical University of 
Lublin, Lublin, Poland (KE-0254/276/2013). ClinicalTrials.gov ID of study is NCT03752606 




The study population consisted of 50 women who had undergone pelvic 
lymphadenectomy for either cervical or endometrial cancer and who had met the 
inclusion/exclusion criteria requirements (Tab. 1). Inclusion criteria for the study included 
women undergoing open hysterectomy and lymphadenectomy for cervical or endometrial 
cancer, age between 18 and 70 years, and the signing of a written informed consent (patients 
had to agree to participate in the study and had to signal their informed consent at least one 
day before surgery). Exclusion criteria included women with previously diagnosed lymph 
edema or disease of the lymphatic system or a known disease of the immune system.  
The prospective randomized clinical intervention trial consisted of 50 open surgeries 
undertaken between 2013-2014 at the 2nd Department of Gynecology in Lublin. The 
participants were centrally randomized by the principal investigator (TR). The case surgeons 
allocated TachoSil (NCT Number: ICMJE NCT01192022; Other Study ID Numbers:  ICMJE 
TC-2402-040-SP; U1111-1130-9121 Registry Identifier: WHO) for one side (left or right) 
after lymphadenectomy. The second side was a control side without TachoSil. Allocation was 
communicated by telephone after informed consent had been obtained and after 
lymphadenectomy had been completed. Outcome assessment was performed by independent 
reviewers who were blinded to the treatment allocation.  
The open surgeries were performed as follows: in women who underwent routine 
pelvic lymphadenectomy, lymph node tissue was removed from the external iliac vessels, the 
obturator fossa, the interiliac region, and the common iliac region after identification and 
appropriate preparation of iliac vessels and obturator nerve. The same amount of lymph node 
tissue was removed from both sides. At the end of the procedure, hemostasis was checked. A 
TachoSil® patch of 4.8 x 4.8 cm was attached to one side of the obturator fossa (study group). 
The same patient also constituted the control group, as no TachoSil® patch was used on the 
second side of the lymphadenectomy. Specific drainage of the retroperitoneum was 
performed. 
Taking into consideration the examined group that the patient was allocated to, the 
surgeon applied either one TachoSil® patch in the study group or no TachoSil® in the control 
group. On TachoSil placement, after four minutes, a uniform pressure was applied to it to 
provide rapid haemostasis by forming a strong fibrin clot adjacent to the tissue surface. The 
TachoSil patch was placed alternately once in the left, once in the right obturator fossa, so that 
each of the patients participating in the study could be their own control. The next step was a 
radical hysterectomy - in case of cervical cancer, and simple hysterectomy - in case of 




After completion of the procedure, the stitching of the vagina to the hollow was 
performed by passing the vaginal seam through the vaginal wall, the right-side sacro-uterus 
ligament, the right round ligament, the peritoneal uterine vesiculitis, the left round ligament, 
the left sacro-uterine ligament and, finally, the vaginal wall. This way of fixation allowed free 
lymphatic drainage of the retroperitoneal space. Two drains from the vicinity of the pits of the 
curtains were removed through the abdominal wall, which were left to the second day after 
surgery or longer if the volume of secretion in the drainage exceeded 40 mL per day. The 
urinary bladder catheter was removed on the third day after surgery and ultrasound after 
voiding (PVR) was evaluated.  
Surgical procedures were performed by four doctors with extensive experience in 
oncological gynecology. The surgical protocols were blinded to other researchers who 
controlled patients in the postoperative period, and the data obtained were then analyzed by an 
independent reviewer. The evaluation criteria of the study were the development of lymph 
cysts and their volume. Antibiotic prophylaxis was implemented according to local hospital 
recommendations. In addition, metronidazole was administered at a dose of 500 mg every 8 
hours. I.V. for the first three days after the procedure. Patients also received small-molecule 
heparin at a dose of 4,000 IU from the day preceding the surgery up to 30 days after its 
completion. Due to lymphatic cysts usually appearing 7 to 15 days after lymphadenectomy, 
the ultrasound examination of the presence and volume of lymphocele was performed on the 
7th and 30th day after the surgery and after completing the oncological complementary 
treatment [1, 11]. The criteria proposed by Tinelli et al., were used to define lymphocele [1]. 
Histopathological report revealed that there was 8.3 ± 1.4 lymph nodes removed from right 
side and 8.5 ± 1.9 from left side (p = 0.56). 
 
Statistical analysis 
The chi-square test was used for comparisons of frequencies and cross-tabulations. 
One Way ANOVA was exploited to generate ranking means. Standard statistical operations 
(means, standard deviations, and ranges) were employed for describing demographic data. 
Bonferroni’s correction was applied for multiple comparisons of secondary outcomes. There 
was no normal distribution, therefore, a non-parametric Mann-Whitney-U test was used for 
statistical comparison. The Wilcoxon-paired test (Z) was enlisted to compare related samples. 






Demographic data  
The mean age of patients was 56 ± 9.5 years old, and median stay in the hospital was 
11.8 ± 8 days, however, seven patients stayed more than 15 days. One day after surgery, 
outflow of clear fluid was observed in 39 (78%) TachoSil Group cases and 40 control group 
cases (80%). Two days after surgery, the same number of cases showed outflow of fluid (36 
or 72%). After six days, outflow of fluid was observed in 16 (32%) TachoSil Group cases and 
13 (26%) control group cases. Thirty days post-operation, outflow of fluid occurred in 11 
(22%) TachoSil Group cases and 22 (44%) control group cases. Finally, two patients of the 
control group had symptomatic lymphocele, while the same number of cases was observed in 
the TachoSil Group (Tab. 2).  
Estimation of the drainage volume with TachoSil application 
  Figure 1 presents the drainage volume (mL) with TachoSil applied. We found a 
significantly difference in drainage volume at day 1 (73.56 ± 73.03 mL) and day 2 (44.30 ± 
80.25 mL; p = 0.004). Moreover, we observed statistical difference between drainage volume 
at day 2 (44.30 ± 80.25 mL) and day 6 (14.68 ± 31.61 mL), respectively.  
Estimation of the drainage volume without TachoSil application 
Figure 2 presents the drainage volume (mL) without TachoSil applied. We found a 
significant difference in drainage volume at day 2 (46.8 ± 51.05 mL) and day 6 (20.4 ± 47.54 
mL; p < 0.001). However, we observed no statistical difference between day 1 (54.2 ± 60.07 
mL) and 2 (46.8 ± 51.05 mL) and between day 6 (20.4 ± 47.54 mL) and day 30 (41.52 ± 
102.07 mL). 
Comparison drainage volume between groups with and without TachoSil 
Figure 3 presents the comparison drainage volume (mL) of the groups with and 
without TachoSil. We found a significantly difference in drainage volume at day 30 (Z = 
2.565; p = 0.01). Here, drainage volume with TachoSil application was lower (M = 14.84 mL) 
in comparison to the control group (without TachoSil) (M = 41.52 mL). In contrast, we 
observed no statistical difference between days 1, 2 or 6. 




In comparing the 22 individuals known to have hypertension to the rest of the study 
population, we found no significant difference in drainage volume at day 1, 2, 6 and 30 
between cases with and without hypertension. 
Comparison of occurrence of lymphocele in patients with endometrial and cervical 
cancer after completing of adjuvant treatment 
Lymphocele was observed in 44% of all control group cases and 22% of all TachoSil 
Group cases 30 days post-surgery. During the first-year follow-up, after completion of 
adjuvant therapy, we observed incidence of lymphocele decline to 18% in general and 12% in 




Most cases of lymphocele are found accidentally during routine medical check-ups. 
Here, small cysts are often asymptomatic and do not require treatment because they are self-
absorbed. Indeed, in the group of patients with clinically symptomatic lymphocele, 
complaints associated with the presence of lymphocele normally result from the mechanism 
of compression of the surrounding anatomical structures and depend on the location and size 
of the lesions [1, 2, 6]. Song et al. [9], indicate that there is a correlation between the number 
of removed lymph nodes and the incidence of lymphocele [9], with the risk of being higher in 
patients with more lymph nodes removed (37.3 v 29.2; p < 0.02). Tinelli et al. [1], and 
Achouri et al. [14], add that the possibility of lymphocele diagnosis should be considered after 
lymphadenectomy in gynecological malignancy, especially when BMI is higher than 25 
kg/m2, a broad lymphadenectomy has been undertaken, metastatic lymph nodes have been 
indicated, the patient is receiving heparin prophylaxis, lymphatic ligation failure has occurred, 
open surgery versus laparoscopy was applied, chemotherapy and radiotherapy has been 
administered.  
Xu et al. [10], described that in women with cervical cancer, asymptomatic 
lymphoceles detected by ultrasound have been noted in up to 11% of all women after pelvic 
lymphadenectomy [1, 10], but in only 2% of all women who had symptomatic lymphocele 
and required a therapeutic intervention [10]. Tinelli et al. [11], showed that in the 
development of asymptomatic lymphoceles, in a comparison of 30 women in whom TachoSil 
had been applied versus 28 women in whom TachoSil had not been applied, a significant 




however, found no significant differences between the two groups in the occurrence of 
symptomatic lymphoceles and associated surgeries [1]. In contrast, in a 60-month follow-up 
study done by Radosa et al. [12] of 102 symptomatic lymphocele patients, in whom 
laparoscopy was initially performed, laparoscopy was reported to be less recurrent when 
TachoSil was used. 
Tinelli et al., conducted two randomized controlled studies assessing the effect of a 
collagen patch covered with human coagulation factors (TachoSil) as a lymphocele 
preventative after pelvic lymphadenectomy was performed in women with endometrial 
cancer. The first study involved 58 patients with diagnosed endometrial cancer subjected to 
hysterectomy and pelvic lymphadenectomy. The first group consisted of 30 patients treated 
with a standard technique followed by the use of TachoSil. The remaining patients were 
treated using standard technique without the use of TachoSil (control). Operational 
parameters were collected, and ultrasound scans were performed on days 7, 14 and 28 post-
surgery to assess the presence and development of both symptomatic and asymptomatic 
lymphocele, as well as to ascertain the need for further surgical intervention. The time and 
volume of drainage was also established. In both groups, the same number of lymph nodes 
was removed. It was shown that in the first group, the volume of drainage was smaller, in 
addition, lymphocele developed in seven patients from the TachoSil Group and in 16 patients 
from the control group. In the TachoSil Group, only three lymphoceles were symptomatic 
versus nine symptomatic in the control group. This represented statistically significant 
differences. What is more, percutaneous drainage was performed in one case in the first group 
and in four cases in the second group. It was concluded that the intraoperative use of TachoSil 
reduces the incidence of postoperative lymphocele after pelvic lymphadenectomy and may be 
considered as an additional therapeutic option in reducing the volume of drainage and 
preventing lymphocele formation [11].  
 In the second study conducted by Tinelli et al., [1], the same postoperative parameters 
were evaluated via ultrasound examination in a scheme analogous to that used in the previous 
study. In the first group, 26 patients underwent pelvic lymphadenectomy and TachoSil was 
applied, in the second group, the control consisting of 29 people, the procedure was 
performed without collagen patch application. In this scenario, it was shown that intra-
operative laparoscopic application of the TachoSil seemed to reduce the rate of incidence of 
lymphocele formation after pelvic lymphadenectomy and provided an additional treatment 




The method used in the above study conducted by Tinelli et al., was used in the 
surgery protocol of the study carried out in our center, with the outcome as described in the 
Results section. Both the difference in prevalence and the volume of lymphocele after using 
TachoSil after 30 days from surgery turned out to be statistically significant (44% in the 
control group versus 22% in the TachoSil Group). In the group of patients on the side of 
which TachoSil was not used, symptomatic cysts tended to form.  
We then re-evaluated the clinical situation after the complementary oncological 
treatment. On doing so, we observed a decreased tendency of occurrence of lymphocele 
following post-adjuvant therapy in the TachoSil Group. Indeed, when compared to the control 
group (without TachoSil application), 12% of the TachoSil Group contracted lymphocele, 
versus 18% of the control group (without TachoSil). In addition, while Simonato et al. [13], 
and Tinelli et al., claim that the application of a collagen-fibrin patch (TachoSil®) reduced the 
number of symptomatic pelvic lymphoceles by at least 66% after 30 days of surgery [1, 11, 
13], in our study, TachoSil decreased lymphocele by about 56% after 30 days of intervention 
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Figure 4. Incidence of lymphocele (%) in the side in which TachoSil was applied versus that 




Table 1. Demographics 
 
Characteristics Patients (n = 50) 
Age (Mean, years) 56 ± 9.5 
BMI (Mean ± SD, kg/m2) 26.84 ± 4.4 
Type of cancer  
             Cervical 4 
             Endometrial 46 
Operations time 89.4 ± 60 min 






Table 2. Amount of cases outflow (mL) of liquid with and without TachoSil 
 
 
Day after surgery TachoSil Control 
N % N % 
Day 1 39 78.0 40 80.0 
Day 2 36 72.0 36 72.0 
Day 6 16 32.0 13 26.0 
Day 30 11 22.0 22 44.0 
 
 
 
